Drug profile · INN
fosphenytoin sodium
CEREBYX
fosphenytoin sodium (CEREBYX) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — fosphenytoin sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
fosphenytoin sodium (CEREBYX) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is fosphenytoin sodium?
fosphenytoin sodium (CEREBYX) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for fosphenytoin sodium?
CEREBYX is a marketed brand name for fosphenytoin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fosphenytoin sodium?
fosphenytoin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.